Sol-Millennium Medical Inc.
Letter data
- Company
- Sol-Millennium Medical Inc.
- Recipient
- Liang Lin | CEO | Sol-Millennium Medical Inc. | 311 S Wacker Drive | Suite 4100 | Chicago | , | IL | 60606-6604 | United States | llin@sol-m.com
- Issue date
- 2025-12-22
- Posted date
- Not available
- FDA office
- Division of Medical Device and Radiological Health Operations Central
- Subject
- Not available
- Product
- Medical Devices
- CMS ID
- 677524
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Sol-Millennium Medical Inc.
MARCS-CMS 677524 —
December 22, 2025
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
VIA Electronic Mail
Product:
Medical Devices
Recipient:
Recipient Name
Liang Lin
Recipient Title
CEO
Sol-Millennium Medical Inc.
311 S Wacker Drive
Suite 4100
Chicago
,
IL
60606-6604
United States
llin@sol-m.com
Issuing Office:
Division of Medical Device and Radiological Health Operations Central
United States
Secondary Issuing Offices
United States
Dear Mr. Lin:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS #677524, dated March 18, 2024.) Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
For Barbara C. Marsden
Acting Director
Office of Regulatory Programs
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Content current as of:
01/05/2026
Regulated Product(s)
Medical Devices